MARTEK BIOSCIENCES (NASDAQ:MATK)

WEB NEWS

Friday, June 4, 2010

Comments & Business Outlook

Three months ended July 31, 2010

 

(in millions, except  per share data)

Martek

Amerifit


Consolidated

 





 

Revenue

$

93.0 – 97.0

$

19.0 – 21.0

$

113.0 – 118.0

 

Income from operations

$

17.0 – 18.0

$

2.0 – 3.0

$

19.0 – 21.0

 

Net  income  


Commenting on the second quarter, Chief Executive Officer Steve Dubin said, "The improving economy, new launches of products with Martek's life'sDHA, growing international markets for Martek's products and sales of Amerifit's branded consumer health products all contributed to Martek's record quarterly results. This year as a whole is looking strong from a revenue perspective, although revenues for the balance of 2010 are projected to be somewhat uneven on a quarter-to-quarter basis due to customer plant shutdowns for maintenance and other timing matters. Martek's strong run rate coming out of fiscal 2010 should provide an excellent platform from which to grow as some of Martek's new products currently in development begin to hit the market over the next eighteen months as additional consumer brands launched through Amerifit's marketing and distribution channels."



Market Data powered by QuoteMedia. Terms of Use